Illumina illékonyság
Mi az Illumina illékonyság?
A illékonyság az Illumina, Inc. - 4.39%
Mi a illékonyság meghatározása?
A volatilitás vagy az átlagos valódi tartomány százalék (ATRP 14) a záróár százalékában kifejezve.
Average true range percent (ATRP) measures volatility on a relative level. This is opposed to the ATR, which measures volatility on an absolute level. ATRP allows securities to be compared whereas ATR does not. That means lower-priced stocks won't necessarily have lower ATR values than higher-priced stocks.
The period used in the calculation is 14 days and the normalized indicator oscillates between 0 and 100 percent of recent price variation. Importantly, the indicator doesn't predict the direction of price but it describes the current volatility. The volatility is comparable across all securities and all markets.
Volatility expresses the degree of price movement. The use of ATRP as volatility compared to ATR is preferred in cases when different securities or different time periods are compared. Examples are stock screening, filtering strategies, and studying seasonality and volatility patterns over long periods of time and different markets
illékonyság a Miscellaneous szektor a LSE-on cégekben a Illumina -hoz képest
Mit csinál Illumina?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has collaboration agreements with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer; LetsGetChecked to track COVID-19 variants in California; and Merck & Co., Inc. to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency. The company was incorporated in 1998 and is headquartered in San Diego, California.
illékonyság -hoz hasonló cégek Illumina
- Baytex nak illékonyság 4.38% van
- Provident plc nak illékonyság 4.38% van
- VCREDIT nak illékonyság 4.38% van
- Tinka Resources nak illékonyság 4.38% van
- KNR Constructions nak illékonyság 4.38% van
- Fidelity RMT-Fidelity SaveEasy 2030 nak illékonyság 4.38% van
- Illumina nak illékonyság 4.39% van
- Advanced Enzyme Technologies nak illékonyság 4.40% van
- Carmat SA nak illékonyság 4.40% van
- Anova Metals nak illékonyság 4.40% van
- Jindal Worldwide nak illékonyság 4.40% van
- ProShares Trust - ProShares UltraPro Short S&P500 nak illékonyság 4.40% van
- Spectral Medical nak illékonyság 4.40% van